PDCD1 and cancer: ICIs block the binding of PD-L1 to PD-1 on immune cells by stimulating the immune system to fight cancer, e.g., as is the case of PD-1 inhibitors (athezolizumab/nivolumab) and PD-L1 inhibitors (pembrolizumab/durvalumab) [77,78].